The Myelin Repair Foundation (MRF) is partnering with the National Institutes of Health (NIH) to conduct a clinical trial on a potential therapeutic that may protect and repair myelin in multiple sclerosis (MS) patients.
Protect the brain. MRF investigators found that this therapeutic—an FDA-approved drug to treat hypertension—may be “neuroprotective.” That is, unlike current MS therapies which all suppress the immune system, MRF-008 — also known as guanabenz — may help protect myelin-producing cells (oligodendrocytes) in the brain from damage.
Advance next-generation treatments. The MRF-008 (guanabenz) clinical trial represents a game-changing opportunity for the MRF and its supporters to help develop next-generation MS therapeutics. Instead of targeting the immune system, such therapeutics will protect and repair myelin—with the potential to transform the lives of MS patients around the world.
“The MRF and the NIH see a tremendous opportunity to investigate the repurposing of this drug to protect and repair myelin in multiple sclerosis patients.”
MRF President, Founder and CEO